<DOC>
	<DOCNO>NCT00046176</DOCNO>
	<brief_summary>This study 48-week study design evaluate safety efficacy fixed-dose combination tablet administer once-a-day versus individual tablet administer twice-a-day within 3-drug combination regimen ART ( antiretroviral ) -experienced HIV-1 infected patient .</brief_summary>
	<brief_title>A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Currently receive initial antiretroviral therapy ( ART ) regimen compose drug abacavir ( ABC ) 300mg twice day , plus drug 3TC ( lamivudine ) 150mg twice day combination either protease inhibitor nonnucleoside reductase inhibitor ( NNRTI ) least 24 week . NOTE : Subjects require change initial protease inhibitor ( PI ) NNRTI therapy due intolerance ( treatment failure ) eligible . Subject must stable regimen second PI NNRTI therapy least 6 month enrollment study . Plasma HIV1 RNA le 400 copies/mL least 3 month immediately precede screen visit , screen . CD4+ cell count least 50 cells/mm3 screening . Written inform consent participate study participation . Male female ( Females childbearing potential must negative serum pregnancy test screen agree acceptable method contraception . ) History CDC Clinical Category C event require treatment ( include cutaneous Kaposi 's sarcoma ) within 45 day screen visit . Treatment acute event must complete least 30 day screen . Subject enrol one investigational drug study may impact HIV RNA suppression . Subject unable complete 48week dosing period , evaluation assessment . Subject pregnant breastfeeding . History clinically relevant inflammation pancreas hepatitis within 6 month prior screen . Subject suffers serious medical condition , diabetes heart problem . Preexisting mental , physical , substance abuse disorder . History inflammatory bowel disease malignancy , intestinal ischemia , malabsorption , gastrointestinal dysfunction . Abnormal laboratory result within 28 day first dose study medication . Required treatment radiation therapy cytotoxic chemotherapeutic agent within 28 day screen , need study . Subject require treatment immunomodulating drug systemic corticosteroid , interleukin , vaccine , interferon within 28 day prior screen , subject receive HIV1 immunotherapeutic vaccine within 90 day prior screen . Asthmatic subject use inhaled corticosteroid eligible enrollment . Subject require treatment foscarnet , hydroxyurea agent document activity HIV1 vitro within 28 day screen . Subject history allergy study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>HIV-1 Abacavir Lamivudine Antiretroviral-experienced</keyword>
</DOC>